Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.62 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.62 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.62 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.62 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.62 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.62 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.62 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.62 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.62 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22222298 | 0.91 | GRIN2D (0.50) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL5328724 | 0.90 | GRIN2D (0.68) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL28320786 | 0.88 | GRIN1 (0.55) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| Eticyclidine SCHEMBL66697 | 0.85 | GRIN2D (0.57) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL9765029 | 0.85 | GRIN2D (0.70) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| Eticyclidine SCHEMBL10669385 | 0.84 | GRIN2D (0.58) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL27075234 | 0.82 | GRIN2D (0.55) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL30151574 | 0.82 | GRIN2D (0.67) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL27561886 | 0.82 | GRIN2D (0.62) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 | |
| SCHEMBL19095278 | 0.81 | MEN1 (0.49) | GRIN2DGRIN3BGRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250106358-A1 | CONTROL METHOD FOR CONTROL OF A VIRTUAL PANEL DISCUSSION OVER A COMMUNICATION LINK BETWEEN A PLURALITY OF COMMUNICATION PARTICIPANTS | Heinlein Support GmbH (DE) | 2025-03-27 | — | — | US | disclosed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | GRIN2D 12/4885GRIN3B 9/4885GRIA1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.